09/2012 p210 transcript b3a2 and b2a2 118.683% IS (88.57%), p190 transcript e1a2 0.01% @ Dx, bone marrow biopsy, t(9;22) translocation in all 20 of the metaphases examined, FISH - 93%, WBC 65.5, began Gleevec 400mg/day, with allopurinol 300mg/day for a few weeks.
12/2012 003.590% IS (1.438%) & bone marrow biopsy - no residual myeloproliferative features but detected 1/20 metaphases containing the Philadelphia chromosome, FISH - 5.5%
2013 000.914% IS (0.813%), 000.434% IS (0.574%), 000.412% IS (0.611%)
10/2013 000.360% IS (0.859%) & bone marrow biopsy - normal male karyotype with no evidence of a clonal cytogenetic abnormality
2014 000.174%, 000.088%, 000.064%
2015 000.049%, decrease to Gleevec 200mg/day, 000.035%, 000.061%, 000.028%
2016 000.041%, 000.039%, 000.025%
2017 000.029%, 000.039%, switched to generic imatinib 200mg/day, 000.070%, 000.088%
2018 000.233%, switched to Sprycel 100mg/day, Sprycel at 100 and then 50 mg/day did not agree with me so I went back to generic imatinib 300mg/day. 000.013% The Sprycel did seem to be effective. It was probably just too high of a dose for me. Went back to a lowered dose of Sprycel, 000.007%, Sprycel at 25 mg/day seems to working, 20mg/day Sprycel or 200mg/day imatinib, 000.006%
2019 000.007%, 000.007%, PCRU - none detected at limit of 0.0069% (however, very weak qualitative amplification is still seen), 000.004%
2020 000.029%, <000.0069% weak positive? (new lab, specimen didn't meet validated stability/temperature requirements), Weak Pos < 0.0069%, 000.0471%, Gleevec 300mg, 000.0447%
2021 000.0558%, 000.1499%, increased to 400 mg/day Gleevec, 000.1043%
2022 000.1290%, 000.0671%. 000.0264%